Provided by Tiger Trade Technology Pte. Ltd.

Astria Therapeutics Inc

12.58
0.0000
Volume:- -
Turnover:40.15M
Market Cap:718.13M
PE:-5.88
High:12.58
Open:12.58
Low:12.58
Close:12.58
52wk High:13.29
52wk Low:3.56
Shares:57.08M
Float Shares:38.38M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1381
EPS(LYR):-1.6784
ROE:-43.15%
ROA:-26.94%
PB:2.47
PE(LYR):-7.50

Loading ...

Astria Therapeutics Shares up 35.7% Premarket on BioCryst's $700 Million Buyout Deal

THOMSON REUTERS
·
Oct 14, 2025

BioCryst to acquire Astria Therapeutics for $13.00 per share

TIPRANKS
·
Oct 14, 2025

BRIEF-BioCryst To Acquire Astria Therapeutics, Strengthening Presence In Hae, Transforming Growth Profile

Reuters
·
Oct 14, 2025

BioCryst Pharmaceuticals to Acquire Astria Therapeutics, Expanding HAE Portfolio and Securing Strategic Financing

Reuters
·
Oct 14, 2025

Astria Therapeutics Inc - BioCryst to Pay $8.55 Cash and 0.59 Shares per Astria Share

THOMSON REUTERS
·
Oct 14, 2025

BioCryst Pharmaceuticals- Deal Valued at $13.00 per Astria Share, $700 Mln Enterprise Value

THOMSON REUTERS
·
Oct 14, 2025

Astria Therapeutics Inc - BioCryst Enters $550 Mln Financing Facility With Blackstone

THOMSON REUTERS
·
Oct 14, 2025

Astria Therapeutics Inc: Expects Cash Portion of Deal Consideration to Be Funded With Cash on Hand & Part of Blackstone Facility

THOMSON REUTERS
·
Oct 14, 2025

Astria Therapeutics announces new clinical trial results and Phase 3 study for navenibart in hereditary angioedema

Reuters
·
Oct 09, 2025

Astria Therapeutics launches Phase 3 ORBIT EXPANSE long term trial of navenibart for hereditary angioedema

Reuters
·
Oct 08, 2025

Astria Therapeutics Initiates the Phase 3 Orbit-Expanse Long-Term Trial of Navenibart in People With Hereditary Angioedema

THOMSON REUTERS
·
Oct 08, 2025

Astria Therapeutics Announces Phase 3 Trial Results and Presents New Data on Navenibart for Hereditary Angioedema at 2025 HAEi Regional Conference

Reuters
·
Oct 03, 2025

Astria Therapeutics Grants Stock Options to New Employees Under 2022 Inducement Plan

Reuters
·
Oct 03, 2025

Astria Therapeutics Receives EMA Approval to Launch Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema Across Europe

Reuters
·
Oct 02, 2025

Astria Therapeutics NOW Enrolling Hae Patients in the European Union for the Phase 3 Alpha-Orbit Trial

THOMSON REUTERS
·
Oct 02, 2025

Astria Therapeutics (ATXS) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Oct 01, 2025

Astria Therapeutics (ATXS) Receives a Buy from Jefferies

TIPRANKS
·
Sep 18, 2025

Astria Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $20 From $16

THOMSON REUTERS
·
Sep 17, 2025

Astria Therapeutics Says STAR-0310 Showed Half-Life of 68 Days in Phase 1a Trial; Shares Up Pre-Bell

MT Newswires Live
·
Sep 17, 2025

Astria Therapeutics Announces Positive Initial Results From the Phase 1a Healthy Subject Trial of Star-0310 at the European Academy of Dermatology and Venereology

THOMSON REUTERS
·
Sep 17, 2025